Ruotsi - ruotsi - Läkemedelsverket (Medical Products Agency)

laboratorios cinfa s.a. - vardenafilhydrokloridtrihydrat - munsönderfallande tablett - 10 mg - vardenafilhydrokloridtrihydrat 11,85 mg aktiv substans; laktosmonohydrat hjälpämne; aspartam hjälpämne

Euroopan unioni - ruotsi - EMA (European Medicines Agency)

sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - agenter för dermatit, med undantag av kortikosteroider - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.

Ruotsi - ruotsi - Läkemedelsverket (Medical Products Agency)

actavis group ptc ehf. - bosentanmonohydrat - filmdragerad tablett - 125 mg - bosentanmonohydrat 129,082 mg aktiv substans

Ruotsi - ruotsi - Läkemedelsverket (Medical Products Agency)

actavis group ptc ehf. - bosentanmonohydrat - filmdragerad tablett - 62,5 mg - bosentanmonohydrat 64,54 mg aktiv substans

Ruotsi - ruotsi - Läkemedelsverket (Medical Products Agency)

medical pharmaquality s.a. - tadalafil - filmdragerad tablett - 2,5 mg - laktosmonohydrat hjälpämne; natriumlaurilsulfat hjälpämne; tadalafil 2,5 mg aktiv substans

Ruotsi - ruotsi - Läkemedelsverket (Medical Products Agency)

medical pharmaquality s.a. - tadalafil - filmdragerad tablett - 5 mg - natriumlaurilsulfat hjälpämne; tadalafil 5 mg aktiv substans; laktosmonohydrat hjälpämne

Ruotsi - ruotsi - Läkemedelsverket (Medical Products Agency)

medical pharmaquality s.a. - tadalafil - filmdragerad tablett - 10 mg - tadalafil 10 mg aktiv substans; natriumlaurilsulfat hjälpämne; laktosmonohydrat hjälpämne

Ruotsi - ruotsi - Läkemedelsverket (Medical Products Agency)

medical pharmaquality s.a. - tadalafil - filmdragerad tablett - 20 mg - natriumlaurilsulfat hjälpämne; laktosmonohydrat hjälpämne; tadalafil 20 mg aktiv substans

Ruotsi - ruotsi - Läkemedelsverket (Medical Products Agency)

sigillata ltd - tadalafil - filmdragerad tablett - 5 mg - laktosmonohydrat hjälpämne; tadalafil 5 mg aktiv substans; natriumlaurilsulfat hjälpämne

Ruotsi - ruotsi - Läkemedelsverket (Medical Products Agency)

sigillata ltd - tadalafil - filmdragerad tablett - 10 mg - tadalafil 10 mg aktiv substans; natriumlaurilsulfat hjälpämne; laktosmonohydrat hjälpämne